文献速递肝病

未经治疗的慢性乙型肝炎感染者中严重血清丙氨酸氨基转移酶发作与乙型肝炎e抗原血清学转换及HBV DNA下降的关联

Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-02-08

研究基于美国与加拿大21个中心的乙型肝炎研究网络观察性队列,纳入1587例未治疗慢性HBV感染成人,中位随访至5年。严重ALT发作(≥10倍正常上限)4年累积发生率为5.7%,发作与HBV DNA更大程度下降及HBeAg丢失相关,但与HBsAg丢失无关,未观察到肝功能失代偿、肝移植或死亡。

要点

  • 严重ALT发作(≥10倍正常上限)4年累积发生率为5.7%。
  • ALT发作患者HBV DNA下降≥1 log10及HBeAg丢失率更高,HBsAg丢失率相似。
  • ALT发作患者中未观察到肝功能失代偿、肝移植或死亡。

核心结论

  • 在大型多种族慢性HBV感染成人队列中,严重ALT发作的累积发生率较低,且与HBV DNA更大程度下降及HBeAg丢失相关,但与HBsAg丢失无关。

研究设计与样本

  • 乙型肝炎研究网络是一项在美国和加拿大21个中心入组未治疗慢性HBV感染成人的观察性队列研究。
  • 共纳入1587例参与者,男性49.9%,亚裔73.7%,B基因型35.2%,平均年龄42.6岁。
  • 入组时、第12周和第24周及此后每24周收集临床和实验室数据,计划随访5年(2011年1月至2016年5月)。
  • 排除有肝功能失代偿史、肝细胞癌、实体器官或骨髓移植、慢性免疫抑制或入组前6个月内接受抗病毒治疗者。
  • ALT发作定义为至少10倍正常上限(男性300 U/L,女性200 U/L)。

主要发现

  • 102例参与者(6%)发生ALT发作,其中31次发作(30%)发生在基线时。
  • ALT发作的4年累积发生率为5.7%。
  • ALT峰值中位水平为450 U/L(第25至75百分位,330 U/L至747 U/L),最高为2578 U/L。
  • 多因素分析中,与ALT发作发生相关的因素包括:男性(OR 3.02;P=.0007)、较高基线HBV DNA值(每log10 OR 1.41;P<.0001)、有风险饮酒(与无或中度饮酒相比OR 2.27;P=.02)及较高FIB-4值(每log2 OR 1.85;P<.0001);年龄较大与ALT发作几率较低相关(每10年OR 0.63;P=.004)。
  • ALT发作患者相比无ALT发作患者,HBV DNA下降≥1 log10的率(HBeAg阳性 vs HBeAg阴性患者分别为每100人年59 vs 23;P=.003)及HBeAg丢失率(每100人年47 vs 15;P=.002)更高,但HBsAg丢失率相似(每100人年4 vs 2;P=.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The incidence and outcomes of alanine aminotransferase (ALT) flares during the natural history of chronic HBV infection has not been determined in a large, racially heterogeneous group of patients in North America. METHODS: We collected data from the Hepatitis B Research Network-an observational cohort study of untreated adults with chronic HBV infection enrolled at 21 sites in the United States and Canada. Clinical and laboratory data were collected from 1587 participants (49.9% male, 73.7% Asian, 35.2% genotype B infection, mean age of 42.6 years) at enrollment, at weeks 12 and 24, and every 24 weeks thereafter for a planned 5 years of follow up (from January 2011 through May 2016). Participants were excluded if they had a history of hepatic decompensation, hepatocellular carcinoma, solid organ or bone marrow transplantation, chronic immune suppression, or antiviral therapy within 6 months before enrollment. Levels of ALT were measured in serum samples and flares were defined as at least 10 times the upper limit of normal (300 U/L in males and 200 U/L in females). RESULTS: ALT flares occurred in 102 participants (6%), with 31 flares (30%) occurring at baseline. The 4-year cumulative incidence of ALT flares was 5.7%. The median peak level of ALT was 450 U/L (25th-75th percentile, 330 U/L to 747 U/L) with a maximum of 2578 U/L. In multivariable analysis, factors associated with the occurrence of an ALT flares were: male sex (odds ratio [OR], 3.02; P=.0007), higher baseline HBV DNA values (OR per log10, 1.41; P<.0001), at risk alcohol use (OR, 2.27 vs none or moderate; P=.02), and higher FIB-4 values (OR, 1.85 per log2; P<.0001). Older age was associated with lower odds of an ALT flare (OR, 0.63 per 10 years; P=.004). Rate of decrease in level of HBV DNA by 1 log10 or more (59 vs 23 per 100 person-years for HB e antigen (HBeAg)-positive vs HBeAg-negative patients; P=.003) and HBeAg loss (47 vs 15 per 100 person-years; P=.002) were higher in patients with an ALT flare than in patients without, but the rate of HBsAg loss was similar (4 vs 2 per 100 person-years; P=.26). No hepatic decompensation, liver transplants, or deaths were observed in participants with ALT flares. CONCLUSION: In a large racially heterogeneous cohort of adults with chronic HBV infection, the cumulative incidence of severe ALT flares was low and associated with greater decreases in HBV DNA and loss of HBeAg, but not with loss of HBsAg.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Brahmania M, Lombardero M, Hansen BE, et al. Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clin Gastroenterol Hepatol. 2019. PMID: 30743006. doi:10.1016/j.cgh.2019.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。